Our latest thinking on biopharmaceutical development and commercialization.
Advances in genomics and information technology are ushering in a new era for oncology drug development, but biopharmaceutical companies must move the conversation from cost to value.
Healthcare costs are climbing, regulators around the globe are requiring more information, and both providers and payers have higher expectations for a medical treatment’s proof of value before prescribing or paying for those treatments.
As the prevalence of diabetes continues to increase globally, and the market for new therapies grows increasingly crowded, it's more important than ever to match the right drug to the right patient.
To turn data into insights, upgraded IT systems are essential. Outdated systems lead to significant costs – in terms of time, frustration and an increased risk of errors. Integrated IT systems are a crucial component in reducing manual processes, resulting in fewer errors, faster processes, far less frustration and ultimately lowering your costs. Benefit from more insightful data analysis, which can lead to groundbreaking discoveries.
Although regulatory incentives and the designation of “orphan” products have stimulated commercial research for rare diseases, their low prevalence, high complexity and predominance in children create significant barriers. Providers and patients are clamoring for treatment access and improved outcomes, but increasingly payers are making hard choices about reimbursing these therapies.
Biosimilar development and commercialization is a uniquely difficult endeavor requiring precise, stepwise planning to ensure timely regulatory approval and optimal market access.